|
Report No. : |
308679 |
|
Report Date : |
07.03.2015 |
IDENTIFICATION DETAILS
|
Name : |
MS PHARMA CORP. |
|
|
|
|
Registered Office : |
31, Galmachi-Ro 244beon-Gil, Jungwon-Gu, Seongnam-Si, Gyeonggi-Do, Rm.319, Hyundai Valley 100-717 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Date of Incorporation : |
01.08.2005 |
|
|
|
|
Com. Reg. No.: |
101-07-31877 |
|
|
|
|
Legal Form : |
Sole Proprietorship |
|
|
|
|
Line of Business : |
Wholesale of Drugs and Pharmaceutical Products, Health Foods. |
|
|
|
|
No. of Employees : |
1 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – December 31, 2014
|
Country Name |
Previous Rating (30.09.2014) |
Current Rating (31.12.2014) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SOUTH KOREA - ECONOMIC OVERVIEW
South Korea over the past
four decades has demonstrated incredible growth and global integration to
become a high-tech industrialized economy. In the 1960s, GDP per capita was
comparable with levels in the poorer countries of Africa and Asia. In 2004,
South Korea joined the trillion-dollar club of world economies, and is
currently the world's 12th largest economy. Initially, a system of close
government and business ties, including directed credit and import
restrictions, made this success possible. The government promoted the import of
raw materials and technology at the expense of consumer goods, and encouraged
savings and investment over consumption. The Asian financial crisis of 1997-98
exposed longstanding weaknesses in South Korea's development model including
high debt/equity ratios and massive short-term foreign borrowing. GDP plunged
by 6.9% in 1998, and then recovered by 9% in 1999-2000. South Korea adopted
numerous economic reforms following the crisis, including greater openness to
foreign investment and imports. Growth moderated to about 4% annually between
2003 and 2007. South Korea's export focused economy was hit hard by the 2008
global economic downturn, but quickly rebounded in subsequent years, reaching
6.3% growth in 2010. The US-Korea Free Trade Agreement was ratified by both
governments in 2011 and went into effect in March 2012. Throughout 2012 and
2013 the economy experienced sluggish growth because of market slowdowns in the
United States, China, and the Eurozone. The administration in 2014 is likely to
face the challenge of balancing heavy reliance on exports with developing
domestic-oriented sectors, such as services. The South Korean economy's long
term challenges include a rapidly aging population, inflexible labor market,
dominance of large conglomerates (chaebols), and heavy reliance on exports,
which comprise about half of GDP.
|
Source
: CIA |
|
Company Name |
MS PHARMA CORP. |
|
Registered Address |
31, Galmachi-ro 244beon-gil, Jungwon-gu,
Seongnam-si, Gyeonggi-do, Korea |
|
Building |
Rm.319, Hyundai Valley |
|
Zip Code |
100-717 |
|
Tel |
+82-2-6205-0831 |
|
Fax |
+82-2-6008-6215 |
|
|
|
|
Trading Address |
Rm.319, Hyundai Valley, 31, Galmachi-ro 244beon-gil,
Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea (Old Address System : Rm.319, Hyundai
Valley, 223-12, Sangdaewon 1-dong, Jungwon-gu, Seongnam-si, Gyeonggi-do,
Korea) |
|
Tel |
+82-2-6205-0831 |
|
Fax |
+82-2-6008-6215 |
|
|
|
|
Type |
Export |
|
Industry |
Wholesale of Pharmaceuticals |
|
Main Business |
Drugs & Pharmaceutical Products, Health Foods |
|
|
|
|
Established (mm/dd/yyyy) |
08/01/2005 |
The Subject Company
occupies the premises of registered HQ address by leasing base.
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
Name |
Ahn Ki-Seung (Mobile : +82-11-485-0831) |
|
Address |
|
|
Date of Birth |
11/09/1966 |
|
Title |
Owner |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital (KRW) |
Not Applicable to
the Sole Proprietorship |
|
Employees |
1 |
|
Formation |
Sole Proprietorship |
|
Bank Details |
N/A |
|
Corporate Registered No. |
Not Applicable to the Sole Proprietorship |
|
Business Registered No. |
101-07-31877 |
|
Permit & Licenses |
N/A |
|
Shareholder Position |
The owner has 100% shares. |
|
Company History |
08/01/2005 Established as the present name |
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
Owner |
Mr. |
Ahn Ki-Seung |
Male |
Korean |
08/01/2005 |
The financials are
not available, and the Subject Company does not have any obligations to release
its financials to the public.
|
Authorized Capital(KRW) |
Not Applicable to the Sole Proprietorship |
|
Paid-Up Capital(KRW) |
Not Applicable to the Sole Proprietorship |
|
Total Issued Shares |
Not Applicable to the Sole Proprietorship |
|
Main Products & Services |
Pharmaceutical Products |
|
Competitors |
GEO-YOUNG CORPORATION 421-1, YEONHUI-DONG, SEODAEMUN-GU, SEOUL,
KOREA TEL:+82-2-3662-8222 FAX:+82-2-3141-6492 BONA MEDICAL SUPPLY CO., LTD. 787, JUNG-RI, DONGTAN-MYEON, HWASEONG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-377-8091 FAX:+82-31-377-8095 BOKSAN PHARM. CO., LTD. 825-13, BEOMIL 2-DONG, DONG-GU, BUSAN,
KOREA TEL:+82-51-667-1511 FAX:+82-51-645-2365 |
Not Available.
Not Available.
---------
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.85 |
|
|
1 |
Rs.94.96 |
|
Euro |
1 |
Rs.69.10 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.